Bayer: FDA OKs Gadavist in Cardiac MR in Adults With Coronary Artery Disease
July 15 2019 - 10:42AM
Dow Jones News
By Colin Kellaher
Bayer AG (BAYN.XE) on Monday said the U.S. Food and Drug
Administration approved the company's Gadavist injection for use in
cardiac magnetic resonance imaging in adults with known or
suspected coronary artery disease.
The Leverkusen, Germany, chemical-and-pharmaceutical company
said Gadavist is the first and only FDA-approved contrast agent for
such use.
Cardiac magnetic resonance imaging is an important diagnostic
tool in the battle against coronary artery disease, which affects
about 16.5 million Americans, Bayer said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 15, 2019 10:27 ET (14:27 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2023 to Mar 2024